Agilent Technologies, Inc. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended October 31, 2017. The filing also provides unaudited fourth-quarter results. Agilent supplies instruments, software, services and consumables to life sciences, diagnostics and applied chemical markets through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab.
Financial performance and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net revenue | $4.472 billion | $4.202 billion |
| Income from operations | $841 million | $615 million |
| Net income from continuing operations | $684 million | $462 million |
| Diluted EPS | $2.10 | $1.40 |
| Gross margin | 53.9% | 52.3% |
| Operating margin | 18.8% | 14.6% |
| Cash from operating activities | $889 million | $793 million |
| Cash and cash equivalents at year-end | $2.678 billion | $2.289 billion |
| Working capital at year-end | $2.906 billion | $2.690 billion |
FY2017 capital expenditures were $176 million; investing activities used $305 million and financing activities used $202 million. The filing does not present free cash flow as a defined metric. Total debt on the balance sheet was approximately $2.011 billion: $210 million short-term and $1.801 billion long-term. The $1 billion revolving facility had $110 million drawn at year-end. About $2.6 billion of cash was held outside the U.S.
Fourth-quarter FY2017 revenue was $1.189 billion, operating income was $233 million, and net income was $177 million. Diluted EPS was $0.54.
Segments and changes versus prior year
- Life Sciences and Applied Markets: Revenue of $2.169 billion, up 5%; operating margin 22.5%, versus 20.7%.
- Diagnostics and Genomics: Revenue of $772 million, up 9%; operating margin 19.3%, versus 16.0%.
- Agilent CrossLab: Revenue of $1.531 billion, up 8%; operating margin 22.1%, versus 22.3%.
Total revenue growth was 6%, compared with 4% in FY2016. Services and other revenue rose 9% to $1.062 billion, faster than product revenue, which rose 6% to $3.410 billion. Growth was broad across segments; management cited strength in pharmaceutical and biotechnology, diagnostics and pathology, and a rebound in chemical and energy markets. Foreign currency reduced FY2017 revenue growth by about one percentage point.
Operating income rose 37% and operating margin expanded four percentage points. Management attributed improvement to higher volume, margin initiatives, lower intangible amortization and transformation and acquisition costs, and a pension settlement gain. FY2017 included a $32 million pension settlement gain, principally associated with returning part of Japan’s pension plan to the Japanese government. The effective tax rate was 14.8%, compared with 15.1% in FY2016; tax audit resolutions and foreign earnings tax accruals affected the rate.
Outlook, risks and notable items
Management described good momentum entering FY2018 but remained cautious about revenue projections because of macroeconomic and political uncertainty and limited end-market visibility. It expected pharmaceutical and biotechnology growth to moderate slightly and lower growth in chemical and energy. It remained optimistic about clinical and diagnostics opportunities, CrossLab near-term demand, and growth across most life sciences and applied markets. No specific consolidated FY2018 revenue or EPS guidance is provided in the supplied filing text.
- Management planned to continue focusing on operating-margin growth, simplifying operations, product differentiation and customer experience, while returning cash through dividends and repurchases. It planned at least 674,000 share repurchases per quarter in FY2018, subject to the program’s terms and conditions.
- Agilent acquired Multiplicom for approximately $72 million and Cobalt Light Systems for approximately $53 million in cash during FY2017. The filing says their pro forma impact was not material.
- The company paid $170 million in dividends and repurchased approximately 4.1 million shares for $194 million during FY2017. A $0.149-per-share dividend was declared after year-end.
- Congress passed U.S. tax legislation on December 20, 2017, but the filing stated it still required presidential signature and Agilent could not yet quantify its effects. The company also identified potential tax effects from repatriating foreign earnings, expiring tax holidays and ongoing tax examinations.
- Key disclosed risks include uncertain customer spending and order timing, competition and product development, foreign currency and international operations, supplier and manufacturing disruption, regulatory and FDA compliance, cybersecurity and IT interruptions, pension-market exposure, debt covenants, and natural disasters. The filing reported no pending legal matters it believed reasonably possible of materially affecting the business or financial statements.
Important facts for investors to verify
- Whether FY2018 revenue trends match management’s cautious view, especially in pharma/biotech and chemical and energy.
- The eventual effect of U.S. tax reform on the effective tax rate, deferred taxes, cash taxes and repatriation of overseas cash.
- Whether margin expansion is sustained after considering the FY2017 pension settlement gain and lower amortization and transformation costs.
- Execution and returns from the Multiplicom and Cobalt acquisitions, and planned capacity investment in nucleic acid solutions.
- Debt repayment and facility usage, foreign-cash accessibility, and continued funding of dividends and share repurchases.
- Renewal of foreign tax holidays, several of which were due between 2018 and 2023, and outcomes of unresolved tax examinations.